Business · 26/02/2026Updated: 10/16/2026 · 1 min read
FDA Determines Regulatory Review Period for REVUFORJ Patent Extension
Summary
The FDA has determined the regulatory review period for REVUFORJ, a human drug product, following a patent extension application submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →